Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK...
15 KB (1,232 words) - 18:26, 20 September 2024
BioPharma. In June 2018, it was approved by the FDA in combination with binimetinib for the treatment of people with unresectable or metastatic BRAF V600E...
11 KB (735 words) - 03:41, 6 August 2024
especially BRAF-mutated melanoma, and KRAS/BRAF mutated colorectal cancer. Binimetinib (MEK162), approved by the FDA in June 2018 in combination with encorafenib...
6 KB (719 words) - 23:12, 12 May 2024
both as a monotherapy and in combination with other agents, such as binimetinib and crizotinib. Cao L, Chen S, Sun R, Ashby CR, Wei L, Huang Z, Chen...
5 KB (183 words) - 16:54, 17 November 2024
C, et al. (2014). "A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical...
18 KB (1,637 words) - 04:59, 12 November 2024
Pfizer acquired the company for approximately $11 billion. MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer TUKYSA...
3 KB (184 words) - 15:23, 7 August 2024
the combination of a BRAF inhibitor encorafenib and a MEK inhibitor binimetinib for the treatment of un-resectable or metastatic melanoma with a BRAF...
154 KB (16,085 words) - 20:20, 6 November 2024
Brigatinib L01ED05 Lorlatinib L01EE01 Trametinib L01EE02 Cobimetinib L01EE03 Binimetinib L01EE04 Selumetinib L01EF01 Palbociclib L01EF02 Ribociclib L01EF03 Abemaciclib...
12 KB (877 words) - 15:36, 25 January 2024
acquisition of two Phase III cancer-drug candidates; the MEK inhibitor binimetinib (MEK 162) and the BRAF inhibitor encorafenib (LGX818), for $85 million...
144 KB (12,146 words) - 09:25, 31 October 2024
vemurafenib. Some MEK inhibitors include cobimetinib, CI-1040, PD0325901, binimetinib (MEK162), selumetinib, and trametinib (GSK1120212) It has been found...
24 KB (3,068 words) - 07:21, 7 June 2024
2147/cmar.s33979. PMC 3421468. PMID 22904643. "FDA approves Encorafenib and Binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations"...
92 KB (12,517 words) - 05:38, 1 October 2024
Fedratinib Filgotinib Lestaurtinib Momelotinib Pacritinib Ruxolitinib MAP2K Binimetinib Cobimetinib Selumetinib Trametinib EML4-ALK Crizotinib Entrectinib Lorlatinib...
12 KB (821 words) - 02:57, 12 October 2024
a new clinical trial evaluating the combination of the MEK inhibitor binimetinib with the autophagy inhibitor hydroxychloroquine in pancreatic cancer...
9 KB (745 words) - 10:16, 7 April 2024
following combinations of ALK inhibitors with MEK inhibitors: brigatinib+binimetinib, ceritinib+trametinib, and alectinib+cobimetinib. Results for the last...
17 KB (1,951 words) - 10:39, 25 January 2024
cells and are implicated in a variety of human tumors e.g. melanoma. Binimetinib (MEK162) has had a phase III clinical trial for NRAS Q61 mutant melanoma...
9 KB (1,205 words) - 02:39, 13 June 2024
Fedratinib Filgotinib Lestaurtinib Momelotinib Pacritinib Ruxolitinib MAP2K Binimetinib Cobimetinib Selumetinib Trametinib EML4-ALK Crizotinib Entrectinib Lorlatinib...
12 KB (758 words) - 23:46, 14 March 2024
ovarian cancer such as low-grade serous cancers. His pivotal study of binimetinib showed activity of this MEK inhibitor in a setting of high unmet need...
28 KB (3,247 words) - 04:38, 28 July 2024